<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11720431</article-id><article-id pub-id-type="pmc">2363961</article-id><article-id pub-id-type="pii">6692118</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.2118</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Malingr&#x000e9;</surname><given-names>M M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Schellens</surname><given-names>J H M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tellingen</surname><given-names>O Van</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ouwehand</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Bardelmeijer</surname><given-names>H A</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Rosing</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Koopman</surname><given-names>F J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Schot</surname><given-names>M E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Huinink</surname><given-names>W W Ten Bokkel</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Beijnen</surname><given-names>J H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam, 1066, The Netherlands</aff><aff id="aff2"><label>2</label>Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Louwesweg 6, Amsterdam, 1066, The Netherlands</aff><aff id="aff3"><label>3</label>Division of Drug Toxicology, Faculty of Pharmacy, Utrecht University, Sorbonnelaan 16, Utrecht, CA, 3584, The Netherlands and</aff><aff id="aff4"><label>4</label>Department of Clinical Chemistry, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam, CX, 1066, The Netherlands</aff><pub-date pub-type="ppub"><month>11</month><year>2001</year></pub-date><volume>85</volume><issue>10</issue><fpage>1472</fpage><lpage>1477</lpage><history><date date-type="received"><day>20</day><month>02</month><year>2001</year></date><date date-type="rev-recd"><day>20</day><month>07</month><year>2001</year></date><date date-type="accepted"><day>30</day><month>07</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The purpose of this study was to investigate the effect of the co-solvents Cremophor EL and polysorbate 80 on the absorption of orally administered paclitaxel. 6 patients received in a randomized setting, one week apart oral paclitaxel 60&#x02008;mg m<sup>&#x02212;2</sup> dissolved in polysorbate 80 or Cremophor EL. For 3 patients the amount of Cremophor EL was 5&#x02008;ml m<sup>&#x02212;2</sup>, for the other three 15&#x02008;ml m<sup>&#x02212;2</sup>. Prior to paclitaxel administration patients received 15&#x02008;mg kg<sup>&#x02212;1</sup> oral cyclosporin A to enhance the oral absorption of the drug. Paclitaxel formulated in polysorbate 80 resulted in a significant increase in the maximal concentration (C <sub>max</sub>) and area under the concentration&#x02013;time curve (AUC) of paclitaxel in comparison with the Cremophor EL formulations (<italic>P</italic> = 0.046 for both parameters). When formulated in Cremophor EL 15&#x02008;ml m<sup>&#x02212;2</sup>, paclitaxel C <sub>max</sub> and AUC values were 0.10 &#x000b1; 0.06&#x02008;&#x003bc;M and 1.29 &#x000b1; 0.99&#x02008;&#x003bc;M h<sup>&#x02212;1</sup>, respectively, whereas these values were 0.31 &#x000b1; 0.06&#x02008;&#x003bc;M and 2.61 &#x000b1; 1.54&#x02008;&#x003bc;M h<sup>&#x02212;1</sup>, respectively, when formulated in polysorbate 80. Faecal data revealed a decrease in excretion of unchanged paclitaxel for the polysorbate 80 formulation compared to the Cremophor EL formulations. The amount of paclitaxel excreted in faeces was significantly correlated with the amount of Cremophor EL excreted in faeces (<italic>P</italic> = 0.019). When formulated in Cremophor EL 15&#x02008;ml m<sup>&#x02212;2</sup>, paclitaxel excretion in faeces was 38.8 &#x000b1; 13.0&#x00025; of the administered dose, whereas this value was 18.3 &#x000b1;15.5&#x00025; for the polysorbate 80 formulation. The results show that the co-solvent Cremophor EL is an important factor limiting the absorption of orally administered paclitaxel from the intestinal lumen. They highlight the need for designing a better drug formulation in order to increase the usefulness of the oral route of paclitaxel &#x000a9; 2001 Cancer Research Campaign &#x02002;&#x02002;<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>paclitaxel</kwd><kwd>oral administration</kwd><kwd>Cremophor EL</kwd></kwd-group></article-meta></front></article>


